Avacta Group PLC - Asset Resilience Ratio
Avacta Group PLC (AVCT) has an Asset Resilience Ratio of 8.33% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Avacta Group PLC to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2020)
This chart shows how Avacta Group PLC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Avacta Group PLC balance sheet assets.
Liquid Assets Composition Over Time
This chart breaks down Avacta Group PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Avacta Group PLC (AVCT) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX5.02 Million | 8.33% |
| Total Liquid Assets | GBX5.02 Million | 8.33% |
Asset Resilience Insights
- Limited Liquidity: Avacta Group PLC maintains only 8.33% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Avacta Group PLC Industry Peers by Asset Resilience Ratio
Compare Avacta Group PLC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 16.06% |
|
Genscript Biotech Corporation
F:G51 |
Biotechnology | 13.79% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 2.66% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
Annual Asset Resilience Ratio for Avacta Group PLC (2016–2020)
The table below shows the annual Asset Resilience Ratio data for Avacta Group PLC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 29.67% | GBX20.02 Million ≈ $2.44K |
GBX67.46 Million ≈ $8.21K |
+16.99pp |
| 2017-07-31 | 12.68% | GBX4.00 Million ≈ $486.68 |
GBX31.55 Million ≈ $3.84K |
-13.95pp |
| 2016-07-31 | 26.63% | GBX10.00 Million ≈ $1.22K |
GBX37.55 Million ≈ $4.57K |
-- |
About Avacta Group PLC
Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more